A Phase 2 Study of PH-10 for the Treatment of Atopic Dermatitis

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

PH-10 is a formulation of rose bengal disodium (RB) for topical administration to the skin. PH-10 is capable of undergoing photochemical reactions when activated by ambient light. This phase 2 study will assess whether topical PH-10 applied once daily to mild, moderate or severe areas of atopic dermatitis (including atopic eczema) may ameliorate inflammation of the skin when activated by ambient light.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Provectus Pharmaceuticals

Criteria

Inclusion Criteria:

• Men or women, age 18 or older.

• Mild, moderate or severe atopic dermatitis.

• Presence of atopic dermatitis areas outside the head and face with a baseline Investigator Global Assessment (IGA) of 2 (mild disease), 3 (moderate) or 4 (severe disease) at screening.

• Written informed consent by the subject or legal guardian.

Exclusion Criteria:

• Women who are pregnant, attempting to conceive, or nursing an infant.

• Subjects who have received phototherapy (UVB, PUVA) or systemic therapy (immunosuppressants, cytostatics, corticosteroids) within 4 weeks.

• Subjects who have received systemic antibiotics within 2 weeks.

• Subjects who have received topical therapy (tar, corticosteroids) within 7 days.

• Subjects who have received investigational drugs in a clinical research study within 4 weeks.

• Subjects who have received agents posing a clinically significant risk of photosensitivity reaction within 5 half-lives of initiation of study treatment.

• Subjects with a history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum.

• Subjects with clinical conditions that may pose a health risk to the subject by being involved in the study or detrimentally affect regular follow-up of the subject.